
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3583152/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	3.3	393
2	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	0.6	383
3	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	3.3	363
4	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	0.6	208
5	The MLL recombinome of acute leukemias. Leukemia, 2006, 20, 777-784.	3.3	196
6	Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 1375-1382.	2.0	188
7	Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7161-7167.	0.8	180
8	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications, 2014, 5, 3469.	5.8	171
9	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	0.6	162
10	Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia, 2009, 23, 1073-1079.	3.3	137
11	Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood, 2002, 100, 4590-4593.	0.6	126
12	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86.	2.2	95
13	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood, 2011, 118, 5559-5564.	0.6	83
14	Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muenster–Based Chemotherapy. Journal of Clinical Oncology, 2008, 26, 283-289.	0.8	69
15	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood, 2014, 123, 1470-1478.	0.6	69
16	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes and Cancer, 2009, 48, 22-38.	1.5	62
17	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	0.6	58
18	Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4568-4573.	3.3	50

#	Article	IF	CITATIONS
19	Detectable Molecular Residual Disease at the Beginning of Maintenance Therapy Indicates Poor Outcome in Children With T-Cell Acute Lymphoblastic Leukemia. Blood, 1997, 90, 1226-1232.	0.6	48
20	Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different Prognosis. Journal of Clinical Oncology, 2011, 29, 1779-1784.	0.8	48
21	Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia, 2015, 29, 38-50.	3.3	48
22	Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Medical and Pediatric Oncology, 2000, 35, 449-455.	1.0	43
23	Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leukemia and Lymphoma, 2012, 53, 1693-1698.	0.6	41
24	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Journal of Clinical Oncology, 2021, 39, 652-662.	0.8	41
25	Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood. Journal of Clinical Oncology, 2007, 25, 5254-5261.	0.8	40
26	Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4 · MLL fusion allele. Leukemia, 2007, 21, 1232-1238.	3.3	40
27	Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large Bâ€Cell Lymphoma treated with the <scp>AIEOP LNH</scp> â€97 protocol. British Journal of Haematology, 2016, 175, 467-475.	1.2	37
28	Assessment of the value of treatment with granulocyte colonyâ€stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. European Journal of Haematology, 1995, 55, 93-96.	1.1	36
29	Risk of Seizures in Children Receiving Busulphan-Containing Regimens for Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 282-285.	2.0	33
30	Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatric Blood and Cancer, 2015, 62, 1906-1913.	0.8	32
31	Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatric Blood and Cancer, 2009, 52, 357-363.	0.8	30
32	Biology of Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2013, 35, 245-252.	0.3	30
33	Clinical manifestations and management of four children with Pearson syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 3063-3066.	0.7	29
34	Longâ€ŧerm results of the AIEOP LNHâ€97 protocol for childhood lymphoblastic lymphoma. Pediatric Blood and Cancer, 2015, 62, 1388-1394.	0.8	25
35	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	3.3	24
36	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	0.8	24

#	Article	IF	CITATIONS
37	Vulvar Melanoma Associated with Lichen Sclerosus in a Child: Case Report and Literature Review. Pediatric Dermatology, 2016, 33, e190-e194.	0.5	22
38	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of Blood and Marrow Transplantation, 2012, 18, 852-860.	2.0	18
39	MLL-MLLT10 fusion in acute monoblastic leukemia: variant complex rearrangements and 11q proximal breakpoint heterogeneity. Cancer Genetics and Cytogenetics, 2004, 152, 108-112.	1.0	15
40	Non-Hodgkin lymphoma in children with an associated inherited condition: A retrospective analysis of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Pediatric Blood and Cancer, 2015, 62, 1782-1789.	0.8	15
41	Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget, 2017, 8, 107886-107898.	0.8	15
42	Singleâ€cell profiling of pediatric Tâ€cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K / Akt and JAK–STAT signaling pathways. Cytometry Part B - Clinical Cytometry, 2020, 98, 491-503.	0.7	13
43	General anesthesia, conscious sedation, or nothing: Decisionâ€making by children during painful procedures. Pediatric Blood and Cancer, 2019, 66, e27600.	0.8	12
44	Marked osteoporosis and spontaneous vertebral fractures in children: Don't forget, it could be leukemia. Medical and Pediatric Oncology, 2003, 41, 450-451.	1.0	11
45	Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL). Pediatric Blood and Cancer, 2004, 42, 278-280.	0.8	11
46	Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer. Journal of Pediatric Hematology/Oncology, 2018, 40, 269-276.	0.3	11
47	Self- and Parent-Reported Psychological Symptoms in Young Cancer Survivors and Control Peers: Results from a Clinical Center. Journal of Clinical Medicine, 2020, 9, 3444.	1.0	10
48	NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 4575.	1.8	10
49	<scp>CD56</scp> , <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€CLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850.	1.1	10
50	REDUCTION IN THE INCIDENCE OF INFECTION BY HEPATITIS C VIRUS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER SUSPENSION OF SAMPLING FROM THE FINGER. Pediatric Infectious Disease Journal, 1996, 15, 265-266.	1.1	10
51	Results of the AIEOP AML 2002/01 Study for Treatment of Children with Acute Myeloid Leukemia Blood, 2009, 114, 17-17.	0.6	9
52	Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Pediatric Blood and Cancer, 2004, 43, 185-185.	0.8	7
53	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. Leukemia, 2009, 23, 199-203.	3.3	7
54	Successful treatment ofFusarium (Spp.) infection in a child with acute lymphoblastic leukemia. , 2000, 34, 356-357.		6

#	Article	IF	CITATIONS
55	Prognostic impact of t(9;11) in childhood acute myeloid leukemia (AML). Leukemia, 2003, 17, 636-636.	3.3	6
56	NEUROLOGICAL COMPLICATIONS DURING TREATMENT OF CHILDHOOD CANCER: Mind Wernicke Encephalopathy. Pediatric Hematology and Oncology, 2010, 27, 320-323.	0.3	6
57	Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). Blood Cancer Journal, 2018, 8, 115.	2.8	6
58	Prenatal origin of <scp>KRAS</scp> mutation in a child with an acute myelomonocytic leukaemia bearing the <i>KMT2A</i> / <i>MLLâ€AFDN</i> / <i>MLLT4</i> / <i>AF6</i> fusion transcript. British Journal of Haematology, 2019, 185, 563-566.	1.2	6
59	Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation. Leukemia, 2007, 21, 360-362.	3.3	5
60	VISCERAL LEISHMANIASIS IN THREE CHILDREN WITH LEUKEMIA. Pediatric Infectious Disease Journal, 1996, 15, 916-918.	1.1	5
61	How to Manage Refractory T-Cell Leukemia-Lymphomas in Children? A Question to Be Answered, Yet!. Blood, 2009, 114, 4777-4777.	0.6	5
62	Natural Killer Lymphoma/Leukemia: An Uncommon Pediatric Case with Indolent Course. Leukemia and Lymphoma, 2004, 45, 1687-1689.	0.6	4
63	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25â€year Italian experience. British Journal of Haematology, 2021, 195, 278-283.	1.2	4
64	Loss of PTEN in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients: Proteomic and Molecular Characterization. Blood, 2014, 124, 2408-2408.	0.6	4
65	Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23). Leukemia, 2014, 28, 1564-1568.	3.3	3
66	FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). Cancers, 2022, 14, 2475.	1.7	3
67	Molecular Pathways in Childhood Acute Lymphoblastic Leukemia: From the Bench to the Bedside. Journal of Pediatric Biochemistry, 2016, 05, 146-156.	0.2	2
68	"Feasible and effective administration of Bortezomib with Rituximab in children with relapsed/resistant B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A step toward the first line― Pediatric Hematology and Oncology, 2019, 36, 438-444.	0.3	2
69	Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology. Frontiers in Oncology, 2021, 11, 663221.	1.3	2
70	Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000 Blood, 2007, 110, 1425-1425.	0.6	2
71	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1071-1071.	0.6	2
72	Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients Blood, 2009, 114, 319-319.	0.6	2

#	Article	IF	CITATIONS
73	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762.	0.6	2
74	Pleuro-pulmonary ultrasound in the diagnosis and follow-up of lung infections in children with cancer: a pilot study. Journal of Ultrasound, 2022, 25, 865-875.	0.7	2
75	Safe administration of muscle-relaxing botulismotoxin during treatment for leukemia. Medical and Pediatric Oncology, 2002, 38, 150-150.	1.0	1
76	T Cell Receptor δ-Chain Gene Rearrangement in a Novel Case of Adult NK Cell Leukemia. Acta Haematologica, 2004, 111, 225-227.	0.7	1
77	Spleen and lung involvement by Acinetobacter calcoaceticus bacteremia mimicking deep fungal infection in a child with acute non-lymphoblastic leukemia. Pediatric Blood and Cancer, 2006, 46, 266-266.	0.8	1
78	Managing hepatosplenic γδT-cell leukemia-lymphoma in children. Pediatric Blood and Cancer, 2007, 49, 763-763.	0.8	1
79	Simultaneous tumors: Acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma. Pediatric Blood and Cancer, 2011, 56, 298-300.	0.8	1
80	Neuroblastoma: Diagnostic and Clinical Aspects. Journal of Pediatric Biochemistry, 2016, 05, 131-138.	0.2	1
81	Tumor Lysis Syndrome: An Emergency in Pediatric Oncology. Journal of Pediatric Biochemistry, 2016, 05, 161-168.	0.2	1
82	Clinical Implications of Minimal Residual Disease Detection in Infants with <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 2020, 136, 41-42.	0.6	1
83	Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy Blood, 2007, 110, 1440-1440.	0.6	1
84	Reverse Phase Protein Assay (RPPA) Defines Specific Patterns in Childhood Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2510-2510.	0.6	1
85	Expression of Annexin 2 in Pediatric B-Acute Lymphoblastic Leukemia: A Marker of Aggressiveness and A Potential Therapeutic Target Blood, 2009, 114, 2605-2605.	0.6	1
86	Downregulation of mTOR and P70S6Kβ2 in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL) Is Correlated with a Poor Prognosis. Blood, 2011, 118, 2508-2508.	0.6	1
87	FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1073-1073.	0.6	1
88	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. Blood, 2014, 124, 3780-3780.	0.6	1
89	Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan Blood, 2009, 114, 2288-2288.	0.6	1
90	Characterization of CD9-CXCL12-CXCR4 Expression in Biological Subtypes of Childhood ACUTE Lymphoblastic Leukemia: Preliminary Findings and Future Perspectives. Blood, 2016, 128, 5278-5278.	0.6	1

#	Article	IF	CITATIONS
91	Clinical Significance of Ck2 (CSNK2) and C-Myc Expression in Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5269-5269.	0.6	1
92	Bilateral adrenal neuroblastoma in the infant: Is it an image-defined risk factor?. Pediatric Hematology and Oncology, 2016, 33, 259-263.	0.3	0
93	Successful Treatment of a Very Late Isolated Relapse in an Adolescent With a PICALM-MLLT10 Positive T-lineage Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2018, 40, e191-e194.	0.3	0
94	Risk of Benign and Malignant Thyroid Disorders in Subjects Treated for Paediatric/Adolescent Neoplasia: Role of Morphological and Functional Screening. Children, 2021, 8, 767.	0.6	0
95	Acute Differentiated Dendritic Cell Leukemia: A New Form of Pediatric Acute Myeloid Leukemia (AML) with MLL Translocations Blood, 2005, 106, 3263-3263.	0.6	Ο
96	TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Blood, 2007, 110, 848-848.	0.6	0
97	Correlation between High Expression of Natural Killer Related-Genes (NCAM/CD94) and Early Death during Induction in Children with Acute Myeloid Leukemia Blood, 2007, 110, 4291-4291.	0.6	Ο
98	Monozygotic Twins with Childhood ALL Demonstrate Prenatal Origin of the Philadelphia Chromosome and Post-Natal Ikaros Deletion Blood, 2009, 114, 87-87.	0.6	0
99	Prevalence and Prognostic Impact of CEBPA mutations in Children with AML Treated with the AIEOP-LAM 2002/01 Protocol Blood, 2009, 114, 2643-2643.	0.6	Ο
100	Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006) Blood, 2009, 114, 1578-1578.	0.6	0
101	Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients Blood, 2009, 114, 2944-2944.	0.6	0
102	In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice Blood, 2009, 114, 1432-1432.	0.6	0
103	Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3585-3585.	0.6	Ο
104	Role of Allogeneic Hematopoietic Stem Cell Transplantation in t(4;11) Positive Acute Lymphoblastic Leukemia (ALL): A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Blood, 2014, 124, 1243-1243.	0.6	0
105	Novel Strategies to Treat Children with Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2015, 126, 4927-4927.	0.6	Ο
106	Abstract 2428: Genetic aberrations in the DNA repair pathway among children with Philadelphia chromosome positive leukemias. , 2016, , .		0
107	Dissecting the DNA Repair Machinery in Biological Subgroups of Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5279-5279.	0.6	0
108	Transcriptomic Profile Identified a Specific Signature in Children with Acute Myeloid Leukemia (AML) and Primary Induction Failure (PIF): Preliminary Data and Future Perspectives. Blood, 2018, 132, 5280-5280.	0.6	0

#	Article	IF	CITATIONS
109	Occurrence of a FAB-M1 AML in a child during treatment of APL: emergence of an immature clone or a therapy related-AML?. Haematologica, 2002, 87, ELT26.	1.7	Ο